Some providers featured on this site may compensate us. This may affect the order and placement of listings but does not influence our editorial ratings or reviews.
Treatments Hub

Verified prices

All verified prices
Guide7 min read

GLP-1s After 65: Medicare's $50 Option Explained (2026)

Medicare's GLP-1 Bridge pilot: a flat $50 a month for Wegovy, the Zepbound KwikPen and Foundayo through December 2027. Who qualifies and the cash alternatives.

Updated October 8, 2026

Medically reviewed on

How we review

The quick answerSince July 1, 2026, the Medicare GLP-1 Bridge pilot lets eligible beneficiaries get the Wegovy pill and injection, the Zepbound KwikPen and Foundayo for a flat $50 copay a month, unchanged as the dose rises, through December 31, 2027. Eligibility runs through clinical criteria and an approval step via your Part D plan. Medicare never covers compounded GLP-1s; if you don't qualify, the cash routes are brand-name ($149-$349 a month for Foundayo, $1,149+ for injections) or compounded ($41-$299).Prices verified on each provider’s site as of November 18, 2026.

Key takeaways

  • Since July 1, 2026, a CMS pilot called the Medicare GLP-1 Bridge lets eligible Medicare beneficiaries get covered obesity drugs for a flat $50 copay a month - the Wegovy pill and injection, the Zepbound KwikPen and the Foundayo pill - with the copay unchanged as doses rise.
  • It is temporary by design: the pilot runs through December 31, 2027, and a longer-term program after that is possible but not promised. Eligibility runs through clinical criteria and an approval step.
  • Medicare never covers compounded GLP-1s. If you don't qualify for the Bridge, the cash options are the same as for everyone else: brand-name direct from the manufacturer or through telehealth, or a compounded version at $41-$299 a month.
  • Older adults are a large share of GLP-1 buyers, and muscle and bone considerations matter more with age - a reason to treat through a clinician who monitors, not a form alone.

What is the Medicare GLP-1 Bridge?

The short answerSince July 1, 2026, the Medicare GLP-1 Bridge pilot lets eligible Medicare beneficiaries get covered obesity drugs for a flat $50 copay a month: the Wegovy pill and injection, the Zepbound KwikPen and the Foundayo pill, with the copay unchanged as doses rise. It runs through December 31, 2027, and eligibility goes through clinical criteria and an approval step. Medicare never covers compounded GLP-1s; if you do not qualify, the cash options are brand-name direct or through telehealth, or a compounded version at $41 to $299 a month.
For years the rule was simple and frustrating: Medicare Part D could cover a GLP-1 prescribed for diabetes but not for weight loss. That changed in 2026. The Centers for Medicare and Medicaid Services launched the Medicare GLP-1 Bridge, a pilot that began on July 1, 2026 and runs through December 31, 2027, under which eligible beneficiaries pay a flat $50 copay at the pharmacy for covered obesity medications. The $50 does not rise as the dose does, which is unusual: on cash prices, dose increases are where the cost climbs. The name is literal - it is meant to bridge to a longer-term program that may or may not begin in 2028.

Our top 2 picks

Our two recommended GLP-1 providers, shown with the same verified pricing and ratings as our full comparison.

Our Top Pick
1
embody logo

Exceptional

9.8out of 10

Compounded GLP-1 from $49/month; not FDA-approved, free expedited delivery

Free expedited deliveryNo hidden fees
  • Compounded semaglutide ($49/mo) and tirzepatide ($99/mo) as shown on the homepage, Nov 16, 2026; not FDA-approved
  • Online intake, then a prescriber review by OpenLoop Health, a network of US-licensed doctors
  • Free expedited delivery (embody's words); the Terms do not guarantee a delivery timeline
  • No insurance required, no clinic visits; cancel at least 72 hours before the next billing date

from $49/month

Doctor-prescribed compounded GLP-1 treatment, not FDA-approved: semaglutide shown at $49/month and tirzepatide at $99/month on embody's homepage (Nov 16, 2026), no insurance required.

Read full embody review
2
altRx logo

Excellent

9.4out of 10

Most Comprehensive GLP-1 Medication Access

Transparent pricingNo insurance required
  • Compounded GLP-1 from $89/mo, GLP-1 + GIP from $149/mo
  • Brand-name options too: Zepbound and Wegovy
  • Clinician-guided - physician, PA, or nurse practitioner
  • Free shipping (about 5-7 days)

from $89/month

Affordable GLP-1 program from $89/month - compounded semaglutide and tirzepatide plus brand-name options - with clinician-guided, self-pay care and no insurance required.

Read full altRx review

Which GLP-1 drugs does Medicare's Bridge cover?

Per the reporting on the program, the pilot covers the Wegovy pill and injection (semaglutide), the KwikPen formulation of Zepbound (tirzepatide) and Foundayo (orforglipron), Eli Lilly's daily pill approved in April 2026. Three things it does not cover: Ozempic or Mounjaro prescribed for weight loss (those are the diabetes labels of the same molecules), any compounded version of any of these - Medicare, like every insurer, does not pay for compounded GLP-1s - and, as far as we can verify, products outside that list. The differences between the brand drugs are in Zepbound vs Wegovy vs Ozempic; the pill-versus-injection choice in GLP-1 pills vs injections.

Who qualifies for the $50 copay, and what should you ask?

Coverage is not automatic. The program applies clinical criteria and requires approval before the $50 copay applies at the counter - the published reporting describes conditions around clinical guidelines and around what happens when the pilot ends.

We have not seen the full eligibility rules in a form we can verify, so we will not summarise them; the right sources are CMS's own program page and your Part D plan. Ask your plan three questions: am I eligible for the GLP-1 Bridge, which of the covered drugs are on your formulary under it, and what documentation does the approval need from my prescriber.

Ask your prescriber one: which of the covered drugs is right for me - a decision made on your history, not on price.

Shop GLP-1 plans by product

The lowest published plans - cheapest first, conditions under each price.

What are the options if you don't qualify?

The cash market is the same one everyone else uses, and it has two tiers. Brand-name. Foundayo lists self-pay prices of $149 to $349 a month by dose through LillyDirect; brand injections run $1,149-$1,799 a month at the telehealth providers we track, detailed in what Zepbound costs online. Compounded. Semaglutide from $41 and tirzepatide from $71 a month at verified published prices, with the trade-offs - not FDA-approved, no trials of its own, never covered by insurance or Medicare - set out in compounded vs brand-name. What $100-$200 a month gets you sorts every option by what you keep paying.

What To Know Before Starting GLP-1 Treatment

Before starting GLP-1 treatment, it's important to understand a few key things. These medications require a prescription from a licensed clinician and aren't suitable for everyone. Some people may experience side effects, especially during the first few weeks as the body adjusts.

GLP-1s also tend to work best when combined with basic lifestyle habits like balanced nutrition and regular physical activity.

That's why choosing a provider that offers proper medical screening and ongoing follow-up support is essential for both safety and long-term success.

Woman preparing GLP-1 weight loss injection

What is different about GLP-1 treatment after 65?

Two things, both clinical. Weight lost on a GLP-1 includes lean mass as well as fat, and preserving muscle and bone matters more with age - which is a case for resistance exercise and adequate protein from the start, and for a clinician who tracks more than the scale.

And medication lists are longer at 65 than at 45, so interactions and existing conditions need a real review. GLP-1 weight loss over 40 and exercise on a GLP-1 cover both. For an older adult, a provider that offers a real clinician conversation and follow-up is worth more than the cheapest row in a price table - our provider comparison covers how each provider handles support.

The bottom line

If you are on Medicare and considering a GLP-1 for weight, ask your Part D plan about the GLP-1 Bridge before you price anything else: $50 a month for a brand-name, FDA-approved drug is the best number on this site, for as long as the pilot lasts. If you don't qualify, the cash options are the same as everyone's, and the month 1 vs year one page shows what each really costs.

Program rules and prices change; everything here is dated and we re-verify. A licensed clinician decides whether treatment is right for you - this page is about paying for it.

Ready to compare weight loss providers?

See how top providers stack up on pricing, medical support, and treatment options.

Medical disclaimer

This page is general information about GLP-1 weight-loss medications such as semaglutide and tirzepatide, published to help you compare services. It is not medical advice, it does not create a doctor-patient relationship, and it is not a substitute for a consultation with a licensed clinician who knows your history. Treatments Hub is not a medical provider, pharmacy or clinic and does not prescribe, sell or dispense medication. Do not start, stop or change any treatment because of something you read here, and do not delay seeking care; in an emergency call 911.

Semaglutide and tirzepatide carry an FDA boxed warning about thyroid C-cell tumours seen in rodents and are not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, nor for use in pregnancy. Compounded versions sold by telehealth providers are prepared by state-licensed pharmacies and are not FDA-approved products. Where a review or post on this page mentions weight lost, that is one person's result and is not typical; results vary widely.

Medical and scientific statements on this site are checked against the sources linked on the page by our medical content reviewer, who does not choose providers or set prices. Prices, plans and customer reviews are each provider's published figures and customers' own words on the dates stated. We may earn a commission from provider links. The full medical and advertising disclaimer explains all of this in detail.

Sources & medical references

Treatment facts on this page are grounded in regulatory guidance and peer-reviewed research. Pricing and plan details come from each provider's published information. This content is for information only and is not medical advice - always consult a licensed clinician before starting treatment.

  1. 1.Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial) - New England Journal of Medicine, 2021
  2. 2.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial) - New England Journal of Medicine, 2022
  3. 3.FDA Approves New Drug Treatment for Chronic Weight Management (semaglutide / Wegovy) - U.S. Food & Drug Administration, 2021
  4. 4.FDA Approves New Medication for Chronic Weight Management (tirzepatide / Zepbound) - U.S. Food & Drug Administration, 2023
  5. 5.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss - U.S. Food & Drug Administration
  6. 6.Human Drug Compounding (503A pharmacy standards) - U.S. Food & Drug Administration
  7. 7.Semaglutide Injection - drug information - MedlinePlus, U.S. National Library of Medicine (NIH)